Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism · 15.10.2024 · 109 (11) · 2709-2719
DOI: 10.1210/clinem/dgae499 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 23.07.2024. Verfasst von Sabitha Sasidharan Pillai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Diabetes Mellitus, Type 2, Obesity, Metabolic Syndrome. Die Arbeit wurde bisher 168-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIDDK NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The gut microbiota (GM), comprising trillions of microorganisms in the gastrointestinal tract, is a key player in the development of obesity and related metabolic disorders, such as type 2 diabetes (T2D), metabolic syndrome (MS), and cardiovascular diseases. This mini-review delves into the intricate roles and mechanisms of the GM in these conditions, offering insights into potential therapeutic strategies targeting the microbiota. The review elucidates the diversity and development of the human GM, highlighting its pivotal functions in host physiology, including nutrient absorption, immune regulation, and energy metabolism. Studies show that GM dysbiosis is linked to increased energy extraction, altered metabolic pathways, and inflammation, contributing to obesity, MS, and T2D. The interplay between dietary habits and GM composition is explored, underscoring the influence of diet on microbial diversity and metabolic functions. Additionally, the review addresses the impact of common medications and therapeutic interventions like fecal microbiota transplantation on GM composition. The evidence so far advocates for further research to delineate the therapeutic potential of GM modulation in mitigating obesity and metabolic diseases, emphasizing the necessity of clinical trials to establish effective and sustainable treatment protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
- Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
- University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, AL 35294, USA.
- Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
ORCID-Profile: Charles A Gagnon, Ambika P Ashraf
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Sasidharan Pillai, S., Gagnon, C. A., Foster, C., & Ashraf, A. P. (2024). Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 109(11), 2709-2719. https://doi.org/10.1210/clinem/dgae499
Vancouver
Sasidharan Pillai S, Gagnon CA, Foster C, Ashraf AP. Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2024;109(11):2709-2719. doi:10.1210/clinem/dgae499
BibTeX
@article{SasidharanPillai2024,
author = {Sasidharan Pillai, Sabitha and Gagnon, Charles A and Foster, Christy and Ashraf, Ambika P},
title = {Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {11},
pages = {2709--2719},
doi = {10.1210/clinem/dgae499}
}
EUVIMED